Is Compounded Semaglutide Legal in 2026? The Complete Answer
Yes — with conditions. FDA enforcement discretion for widespread compounding ended April 22, 2025. Compounded semaglutide remains legal through 503A pharmacies in 2026, but the rules have changed significantly. Here is exactly what is allowed, what ended, and what it means for patients.
Key takeaways
Compounded semaglutide is still legal in 2026 through 503A pharmacies under a valid patient-specific prescription with documented individual clinical justification.
FDA enforcement discretion for widespread compounding ended April 22, 2025, after the semaglutide shortage was declared resolved on February 21, 2025.
503B outsourcing facilities can no longer legally compound semaglutide. 503A pharmacies remain the legal pathway.
Cost preference alone is not sufficient justification. Individual clinical need must be documented by the prescribing provider.
A district court upheld FDA enforcement against 503B compounded semaglutide in April 2025 (OFA v. FDA, N.D. Tex.).
The direct answer
Compounded semaglutide is legal in 2026 — but only through 503A compounding pharmacies, under a valid patient-specific prescription, with documented individual clinical justification from a licensed provider. The era of broad enforcement discretion that enabled widespread GLP-1 compounding from 2022 to 2025 is over. What remains is a narrower, more structured legal pathway that legitimate 503A platforms like Ondra Health operate within.
The full timeline
Key regulatory dates
March 2022 — FDA adds semaglutide to the drug shortage list. 503A and 503B pharmacies may legally compound at scale.
December 2022 — Tirzepatide added to shortage list.
December 19, 2024 — FDA declares tirzepatide shortage resolved.
February 18, 2025 — 503A enforcement discretion for tirzepatide ends.
February 21, 2025 — FDA declares semaglutide shortage resolved.
March 19, 2025 — 503B enforcement discretion for tirzepatide ends.
April 22, 2025 — 503A enforcement discretion for semaglutide ends.
April 24, 2025 — District court denies injunction in OFA v. FDA, upholding 503B enforcement.
May 22, 2025 — 503B enforcement discretion for semaglutide ends.
2026 (ongoing) — 503A pharmacies may still legally compound semaglutide and tirzepatide with documented individual clinical justification.
What 'individual clinical justification' actually means
This is the phrase most platforms skip past — and the one patients most need to understand. Under current FDA policy, a 503A pharmacy may legally compound semaglutide for a specific patient when the prescribing provider documents an individual clinical justification beyond cost preference alone.
Acceptable justifications include a documented allergy or sensitivity to an inactive ingredient in the FDA-approved product, a clinical need for an alternative strength or dosage form not commercially available, or other individualized clinical reasons the provider documents in the patient's record.
What is not sufficient
Cost preference alone is explicitly not an acceptable justification under the "essentially a copy" standard in the FD&C Act. A prescription issued solely because compounded semaglutide is cheaper than Wegovy is not compliant with current FDA policy. At Ondra Health, prescriptions are issued solely at the clinical discretion of licensed providers at Wasef Health, PC, who evaluate each patient individually.
503A vs 503B: which is legal in 2026
503A pharmacies — still legal
State-licensed compounding pharmacies operating under Section 503A of the FD&C Act may still compound semaglutide and tirzepatide for individual patients under valid patient-specific prescriptions with documented clinical justification. All of Ondra Health's pharmacy partners operate under 503A licensure.
503B outsourcing facilities — no longer legal
FDA-registered 503B outsourcing facilities that produce medications in larger batches without patient-specific prescriptions can no longer legally compound semaglutide or tirzepatide. A district court denied a preliminary injunction against FDA enforcement in April 2025. In April 2026, FDA proposed formally excluding both drugs from the 503B bulks list.
What to verify when choosing a platform
If you are receiving compounded semaglutide through a telehealth platform in 2026, your medication is legal provided the prescription was issued by a licensed provider with documented individual clinical justification through a named 503A pharmacy. The red flags to watch for:
The pharmacy is not named publicly. If a platform does not tell you which pharmacy fills your prescription, you cannot verify it is operating under 503A — not 503B or an unregistered source.
No clinical intake process. Platforms that ship GLP-1s with minimal or no clinical evaluation are not meeting the "individual clinical justification" standard.
Suspiciously low pricing with no pharmacy disclosure. 503B facilities had lower per-unit costs than 503A pharmacies. Platforms pricing far below market rates without pharmacy transparency may be sourcing from non-compliant channels.
Frequently asked questions
Is compounded semaglutide the same as Ozempic or Wegovy?
No. Compounded semaglutide contains the same active molecule but is not FDA-approved and is not therapeutically equivalent to Ozempic or Wegovy. The FDA has not reviewed compounded semaglutide for safety, effectiveness, or manufacturing quality. It is prepared by a 503A compounding pharmacy under a patient-specific prescription.
Can I still get compounded semaglutide now that the shortage is resolved?
Yes — through 503A pharmacies, with a valid patient-specific prescription and documented individual clinical justification. The shortage resolution ended the broad enforcement discretion that allowed 503B facilities to compound it, but 503A compounding with proper clinical justification remains legal.
Does Ondra Health comply with current FDA rules?
Yes. Ondra works exclusively with 503A pharmacy partners. All prescriptions are issued by licensed providers at Wasef Health, PC with individual clinical evaluation. Ondra does not source medication through 503B outsourcing facilities.
What is the 'essentially a copy' rule?
The 'essentially a copy' provision in the FD&C Act prohibits compounders from producing medications that are copies of commercially available FDA-approved drugs without individual clinical justification. After the semaglutide shortage resolved, compounding semaglutide solely on the basis of cost is no longer compliant. Individual clinical justification documented by the prescribing provider is required.
† This article is for informational purposes only and does not constitute legal or medical advice. Regulatory information is current as of June 2026. The GLP-1 regulatory environment has been evolving rapidly — verify current FDA guidance directly for the most up-to-date status. Compounded medications are not FDA-approved.